Nature Communications (Oct 2023)

Decreased liver B vitamin-related enzymes as a metabolic hallmark of cancer cachexia

  • Yasushi Kojima,
  • Emi Mishiro-Sato,
  • Teruaki Fujishita,
  • Kiyotoshi Satoh,
  • Rie Kajino-Sakamoto,
  • Isao Oze,
  • Kazuki Nozawa,
  • Yukiya Narita,
  • Takatsugu Ogata,
  • Keitaro Matsuo,
  • Kei Muro,
  • Makoto Mark Taketo,
  • Tomoyoshi Soga,
  • Masahiro Aoki

DOI
https://doi.org/10.1038/s41467-023-41952-w
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 23

Abstract

Read online

Abstract Cancer cachexia is a complex metabolic disorder accounting for ~20% of cancer-related deaths, yet its metabolic landscape remains unexplored. Here, we report a decrease in B vitamin-related liver enzymes as a hallmark of systemic metabolic changes occurring in cancer cachexia. Metabolomics of multiple mouse models highlights cachexia-associated reductions of niacin, vitamin B6, and a glycine-related subset of one-carbon (C1) metabolites in the liver. Integration of proteomics and metabolomics reveals that liver enzymes related to niacin, vitamin B6, and glycine-related C1 enzymes dependent on B vitamins decrease linearly with their associated metabolites, likely reflecting stoichiometric cofactor-enzyme interactions. The decrease of B vitamin-related enzymes is also found to depend on protein abundance and cofactor subtype. These metabolic/proteomic changes and decreased protein malonylation, another cachexia feature identified by protein post-translational modification analysis, are reflected in blood samples from mouse models and gastric cancer patients with cachexia, underscoring the clinical relevance of our findings.